Eye scan for diabetes! Berkshire startup develops breakthrough medical technology with £ 2.85million funding
Repeated finger blood tests with all the pain, discomfort, and inconvenience this brings to people with diabetes may soon become a thing of the past. A revolutionary device that will allow the 4.7 million people with diabetes in the UK to monitor their blood sugar levels with a simple eye scan is about to emerge. Berkshire-based startup Occuity has received investment funding to move forward with the development of Occuity Indigo, the highly innovative contactless optical blood glucose meter.
The largest medtech funding agreement on Seedrs
Founded in 2019 by Dr Dan Daly and Dr Robin Taylor, the vision of the startup is to use the eye as a window into the health of the body. The UK-based medical technology company, which specializes in the research, design and production of portable contactless optical instruments for use in healthcare, diagnostics and monitoring, has lifted the biggest contract of medtech funding (£ 2.85 million) on the main crowdfunding platform, Seeders to develop Indigo. The initial target of £ 1.8million was reached within 24 hours of the launch.
Glaucoma, myopia and diabetes management
The deal is groundbreaking for people with diabetes, but has caught the attention of investors due to the potential wide use of the company’s patented optical technology for a range of conditions, including glaucoma, nearsightedness, diabetes management, prediabetes screening and, hopefully, early detection of Alzheimer’s disease.
Over 850 investors from 37 countries
Occuity CEO and Co-Founder Dr Dan Daly comments, “We are thrilled to have become the biggest medical technology raise ever on Seedrs with over 850 investors from 37 countries sharing our vision. Diabetes is a growing global problem and we believe our technology will enable health services around the world to monitor and screen for diabetes, improving clinical outcomes for the hundreds of millions of people who are unaware they have diabetes. prediabetes or diabetes. The Occuity Indigo will then make regular blood sugar testing easier, faster and painless, improving the daily lives of several million more people around the world.
Repeated blood tests on the finger, no more
Design Director Daniele De Iuliis, who – after spending 27 years with Apple’s Industrial Design Group – now heads the design of Occuity Indigo, comments: “For too long now, the way we let’s find out and watch for chronic diseases like diabetes has been routed in repeated finger blood tests with all the pain, discomfort and inconvenience that comes with it. In contrast, the Occuity Indigo will be a discreet portable product that will simply scan the eye to take a blood sugar measurement offering a 21st long overdue solution of the century.
How will this technology work
Optical confocal scanning technology enables highly precise measurements of structures inside the eye, down to the micron level. The scanning technology will detect the concentration of advanced glycation end products (AGEs) that build up in the eye over time. The invisible “blue” light illuminates the eye and the blue light scattered back alongside the green fluorescent light from the EFAs is detected. Coupled with machine learning techniques, readings from this device will indicate whether the subject is non-diabetic, prediabetic, or diabetic. Taking only a few seconds, the test is completely non-contact, so it can be performed in a non-clinical setting in a pharmacy, optician’s office, or even in a residential setting such as a nursing home.
Blood glucose monitoring (Occuity Indigo)
The Occuity Indigo will be based on the company’s core optical confocal scanning technology. The personal-use device will analyze the aqueous humor of the eye in the anterior chamber of the eye. It is contactless, fast and completely painless. Aqueous humor is actually an ultrafiltrate of blood, that is, blood from which red and white blood cells are filtered. This means that the glucose levels in it correlate very well with those in the blood.